{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:15:00Z","timestamp":1793060100442,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ceftolozane\/tazobactam is a novel cephalosporin\/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane\/tazobactam were compared with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant P. aeruginosa. Multivariate logistic regression was performed controlling for factors associated with treatment to assess the independent impact of ceftolozane\/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 200 patients were included (100 in each treatment arm). The cohort represented an ill population with 69% in the intensive care unit, 63% mechanically ventilated, and 42% in severe sepsis or septic shock at infection onset. The most common infection type was ventilator-associated pneumonia (52%); 7% of patients were bacteremic. Combination therapy was more commonly used in polymyxin\/aminoglycoside patients than those who received ceftolozane\/tazobactam (72% vs 15%, P &amp;lt; .001). After adjusting for differences between groups, receipt of ceftolozane\/tazobactam was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% confidence interval [CI], 1.31\u20135.30) and protective against AKI (aOR, 0.08; 95% CI, 0.03\u20130.22). There was no difference in in-hospital mortality. The number needed to treat for a clinical cure with ceftolozane\/tazobactam was 5, and the number needed to harm with AKI with a polymyxin\/aminoglycoside was 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data support the preferential use of ceftolozane\/tazobactam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz816","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T15:28:14Z","timestamp":1567610894000},"page":"304-310","source":"Crossref","is-referenced-by-count":189,"title":["Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa"],"prefix":"10.1093","volume":"71","author":[{"given":"Jason M","family":"Pogue","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S","family":"Kaye","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Veve","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science, University of Tennessee College of Pharmacy, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twisha S","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T","family":"Gerlach","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, the Ohio State University Wexner Medical Center, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Henry Ford Hospital, Ann Arbor, Michigan; College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A","family":"Puzniak","sequence":"first","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom M","family":"File","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Summa Health, Northeast Ohio Medical University, Rootstown, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Olson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sinai Grace Hospital; Detroit Medical Center, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorabh","family":"Dhar","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Detroit Medical Center, Wayne State University School of Medicine, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perez","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"2020071109144187700_CIT0001","author":"Centers for Disease Control and Prevention"},{"key":"2020071109144187700_CIT0002","volume-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","author":"World Health Organization","year":"2017"},{"key":"2020071109144187700_CIT0003","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jhm.2080","article-title":"Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009","volume":"8","author":"Zilberberg","year":"2013","journal-title":"J Hosp Med"},{"key":"2020071109144187700_CIT0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","article-title":"Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015\u20132016","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020071109144187700_CIT0005","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109144187700_CIT0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2018.11.008","article-title":"Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies","volume":"94","author":"Oliota","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020071109144187700_CIT0007","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020071109144187700_CIT0008","doi-asserted-by":"crossref","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109144187700_CIT0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020071109144187700_CIT0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2020071109144187700_CIT0011","doi-asserted-by":"crossref","first-page":"e01858","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109144187700_CIT0012","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2020071109144187700_CIT0013","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020071109144187700_CIT0014","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020071109144187700_CIT0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020071109144187700_CIT0016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"key":"2020071109144187700_CIT0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2020071109144187700_CIT0018","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1128\/AAC.00868-15","article-title":"Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii clinical isolates","volume":"59","author":"Dafopoulou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109144187700_CIT0019","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/ofid\/ofy209.170","article-title":"Re-appraisal of aminoglycoside (AG) susceptibility testing breakpoints based on the application of pharmacokinetics\u2013pharmacodynamics (PK-PD) and contemporary microbiology surveillance data","volume":"5","author":"Bhavnani","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz816\/30126373\/ciz816.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/2\/304\/33486200\/ciz816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/2\/304\/33486200\/ciz816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T09:57:14Z","timestamp":1664272634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/2\/304\/5572677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,23]]},"published-print":{"date-parts":[[2020,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz816","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,15]]},"published":{"date-parts":[[2019,9,23]]}}}